DGIdb - TEMSIROLIMUS Drug Record

TEMSIROLIMUS chembl:CHEMBL1201182 ApprovedAntineoplasticImmunotherapy

Alternate Names:

CCI-779
TORISEL
TEMSIROLIMUS
CCI 779
TORISEL®
42-[3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPANOATE]RAPAMYCIN
drugbank:06287
pubchem.compound:6918289
rxcui:657797
chembl:CHEMBL1201182
chemidplus:162635-04-3

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Pharmaceutical Developer	Wyeth Pharmaceuticals
Source Reported Drug Name(s)	Temsirolimus
Drug Class	mTOR Inhibitor
Notes	rapalogue
Drug Class	Kinase Inhibitors
FDA Approval	Renal cell carcinoma
Year of Approval	2007
Drug Class	antineoplastic agents, protein kinase inhibitors

(12 More Sources)

Publications:

Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
Weigelt et al., 2013, PI3K pathway dependencies in endometrioid endometrial cancer cell lines., Clin. Cancer Res.
Neshat et al., 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR., Proc. Natl. Acad. Sci. U.S.A.
Patard et al., 2008, Targeted therapy in renal cell carcinoma., World J Urol
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Radulovic et al., 2007, Sunitinib, sorafenib and mTOR inhibitors in renal cancer., J BUON
Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
Liu et al., 2009, Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin., Cancer Res.
Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
Grünwald et al., 2015, TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)., Ann. Oncol.
Liu et al., 2011, The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway., J. Clin. Endocrinol. Metab.
Janku et al., 2012, PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations., J. Clin. Oncol.
Fleming et al., 2012, Phase II trial of temsirolimus in patients with metastatic breast cancer., Breast Cancer Res. Treat.
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
Gandhi et al., 2014, Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors., J. Clin. Oncol.
Thomas et al., 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer., Nat. Med.
Villaruz et al., 2014, Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation., Lung Cancer
Wen et al., 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02., Neuro-oncology
Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol
Moulder et al., 2015, Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer., Ann. Oncol.

TEMSIROLIMUS FBXW7

Interaction Score: 1.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
24360397

Sources:
JAX-CKB
TEMSIROLIMUS NF2

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25878190

Sources:
CIViC
TEMSIROLIMUS VHL

Interaction Score: 0.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16341243

Sources:
CIViC
TEMSIROLIMUS CTNNB1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
27016228

Sources:
JAX-CKB
TEMSIROLIMUS MTOR

Interaction Score: 0.42

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
18265991 11752352 17935273

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND GuideToPharmacology CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB
TEMSIROLIMUS PIK3CA

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Clinical Study

PMIDs:
19706758 27893038 25527417 21289267 22271473 22245973 27016228 21216929

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
TEMSIROLIMUS FKBP1A

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction FK506-binding protein 1A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TEMSIROLIMUS PTEN

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type no benefit

Approval Status Phase II

PMIDs:
27016228 23674493 11504908

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
TEMSIROLIMUS KRAS

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy SCH772984 + Temsirolimus

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
21216929 26725216 27016228

Sources:
ClearityFoundationBiomarkers JAX-CKB
TEMSIROLIMUS BRAF

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Bevacizumab + Temsirolimus + Doxil

Indication/Tumor Type ovarian carcinoma

Response Type sensitive

PMIDs:
21216929

Sources:
JAX-CKB MyCancerGenomeClinicalTrial
TEMSIROLIMUS AKT1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type predicted – sensitive

PMIDs:
27016228

Sources:
JAX-CKB
TEMSIROLIMUS NR1I2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28676933

Sources:
PharmGKB
TEMSIROLIMUS ERBB2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type predicted – sensitive

PMIDs:
24323026

Sources:
JAX-CKB
TEMSIROLIMUS EGFR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy Temsirolimus + Erlotinib

Indication/Tumor Type malignant glioma

PMIDs:
24470557

Sources:
JAX-CKB
TEMSIROLIMUS ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28676933

Sources:
PharmGKB

TEND: TEMSIROLIMUS
- Version: 01-August-2011
Alternate Names:

TEMSIROLIMUS Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, protein kinase inhibitors

Year of Approval 2007

Publications:
CancerCommons: TEMSIROLIMUS
- Version: 25-July-2013
Alternate Names:

6918289 PubChem Drug ID

Temsirolimus Drug Development Name

Temsirolimus PubChem Drug Name

Drug Info:

Drug Class mTOR Inhibitor

Source Reported Drug Name(s) Temsirolimus

Pharmaceutical Developer Wyeth Pharmaceuticals

Publications:
MyCancerGenome: TEMSIROLIMUS
- Version: 20-Jun-2017
Alternate Names:

CCI-779 Development Name

TEMSIROLIMUS Generic Name

TORISEL Trade Name

Drug Info:

FDA Approval Renal cell carcinoma

Drug Class Kinase Inhibitors

Notes rapalogue

Publications:
TdgClinicalTrial: TEMSIROLIMUS
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

PharmGKB: temsirolimus

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol

JAX-CKB: Temsirolimus

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.

Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.

Wen et al., 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02., Neuro-oncology

CIViC: TEMSIROLIMUS

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Liu et al., 2009, Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin., Cancer Res.

Thomas et al., 2006, Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer., Nat. Med.

Moulder et al., 2015, Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer., Ann. Oncol.

TTD: Temsirolimus
- Version: 2020.06.01
Alternate Names:

D0ES1Q TTD Drug ID

Drug Info:

Publications:
TALC: TEMSIROLIMUS
- Version: 12-May-2016
Alternate Names:

CCI-779 Drug Synonym

TEMSIROLIMUS Drug Generic Name

TEMSIROLIMUS Primary Drug Name

Drug Info:

Publications:
GuideToPharmacology: 178102515
- Version: 29-September-2020
Alternate Names:

TEMSIROLIMUS GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201182
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201182
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: TEMSIROLIMUS
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: TEMSIROLIMUS
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: TEMSIROLIMUS
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
OncoKB: Temsirolimus
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	lung adenocarcinoma
Response Type	sensitive
Approval Status	Clinical Study

Indication/Tumor Type	endometrial cancer
Response Type	predicted – sensitive
Approval Status	Phase II

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Indication/Tumor Type	colorectal cancer
Response Type	sensitive
Approval Status	Clinical Study

Mechanism of Interaction	FK506-binding protein 1A inhibitor
Direct Interaction	yes

combination therapy	SCH772984 + Temsirolimus
Indication/Tumor Type	pancreatic ductal adenocarcinoma
Response Type	sensitive

combination therapy	Bevacizumab + Temsirolimus + Doxil
Indication/Tumor Type	ovarian carcinoma
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Phase II
Response Type	predicted – sensitive

Response Type	no benefit
combination therapy	Temsirolimus + Erlotinib
Indication/Tumor Type	malignant glioma

6918289	PubChem Drug ID
Temsirolimus	Drug Development Name
Temsirolimus	PubChem Drug Name

CCI-779	Development Name
TEMSIROLIMUS	Generic Name
TORISEL	Trade Name

CCI-779	Drug Synonym
TEMSIROLIMUS	Drug Generic Name
TEMSIROLIMUS	Primary Drug Name

TEMSIROLIMUS Drug Record

TEMSIROLIMUS chembl:CHEMBL1201182 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung adenocarcinoma Response Type sensitive Approval Status Clinical Study

PMIDs: 24360397

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25878190

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16341243

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type endometrial cancer Response Type predicted – sensitive Approval Status Phase II

PMIDs: 27016228

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 18265991 11752352 17935273

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND GuideToPharmacology CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type sensitive Approval Status Clinical Study

PMIDs: 19706758 27893038 25527417 21289267 22271473 22245973 27016228 21216929

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction FK506-binding protein 1A inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type endometrial cancer Response Type no benefit Approval Status Phase II

PMIDs: 27016228 23674493 11504908

Sources: ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy SCH772984 + Temsirolimus Indication/Tumor Type pancreatic ductal adenocarcinoma Response Type sensitive

PMIDs: 21216929 26725216 27016228

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy Bevacizumab + Temsirolimus + Doxil Indication/Tumor Type ovarian carcinoma Response Type sensitive

PMIDs: 21216929

Sources: JAX-CKB MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase II Response Type predicted – sensitive

PMIDs: 27016228

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28676933

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Phase I Response Type predicted – sensitive

PMIDs: 24323026

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Response Type no benefit combination therapy Temsirolimus + Erlotinib Indication/Tumor Type malignant glioma

PMIDs: 24470557

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28676933

Sources: PharmGKB

TEND: TEMSIROLIMUS

Alternate Names: TEMSIROLIMUS Primary Drug Name

Drug Info: Drug Class antineoplastic agents, protein kinase inhibitors Year of Approval 2007

Publications:

CancerCommons: TEMSIROLIMUS

Alternate Names: 6918289 PubChem Drug ID Temsirolimus Drug Development Name Temsirolimus PubChem Drug Name

Drug Info: Drug Class mTOR Inhibitor Source Reported Drug Name(s) Temsirolimus Pharmaceutical Developer Wyeth Pharmaceuticals

Publications:

MyCancerGenome: TEMSIROLIMUS

Alternate Names: CCI-779 Development Name TEMSIROLIMUS Generic Name TORISEL Trade Name

Drug Info: FDA Approval Renal cell carcinoma Drug Class Kinase Inhibitors Notes rapalogue

Publications:

TdgClinicalTrial: TEMSIROLIMUS

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung adenocarcinoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
24360397

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
25878190

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
16341243

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
27016228

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
18265991 11752352 17935273

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND GuideToPharmacology CancerCommons MyCancerGenomeClinicalTrial TTD OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Clinical Study

PMIDs:
19706758 27893038 25527417 21289267 22271473 22245973 27016228 21216929

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction FK506-binding protein 1A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type no benefit

Approval Status Phase II

PMIDs:
27016228 23674493 11504908

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy SCH772984 + Temsirolimus

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
21216929 26725216 27016228

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy Bevacizumab + Temsirolimus + Doxil

Indication/Tumor Type ovarian carcinoma

Response Type sensitive

PMIDs:
21216929

Sources:
JAX-CKB MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type predicted – sensitive

PMIDs:
27016228

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
28676933

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type predicted – sensitive

PMIDs:
24323026

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy Temsirolimus + Erlotinib

Indication/Tumor Type malignant glioma

PMIDs:
24470557

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
28676933

Sources:
PharmGKB

Alternate Names:

TEMSIROLIMUS Primary Drug Name

Drug Info:

Drug Class antineoplastic agents, protein kinase inhibitors

Year of Approval 2007

Alternate Names:

6918289 PubChem Drug ID

Temsirolimus Drug Development Name

Temsirolimus PubChem Drug Name

Drug Info:

Drug Class mTOR Inhibitor

Source Reported Drug Name(s) Temsirolimus

Pharmaceutical Developer Wyeth Pharmaceuticals

Alternate Names:

CCI-779 Development Name

TEMSIROLIMUS Generic Name

TORISEL Trade Name

Drug Info:

FDA Approval Renal cell carcinoma

Drug Class Kinase Inhibitors

Notes rapalogue

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol

Alternate Names:

D0ES1Q TTD Drug ID

Alternate Names:

CCI-779 Drug Synonym

TEMSIROLIMUS Drug Generic Name

TEMSIROLIMUS Primary Drug Name

Alternate Names:

TEMSIROLIMUS GuideToPharmacology Ligand Name